These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
352 related articles for article (PubMed ID: 31960079)
21. Use of biologics and other novel therapies for the treatment of systemic sclerosis. Bruni C; Praino E; Allanore Y; Distler O; Gabrielli A; Iannone F; Matucci-Cerinic M Expert Rev Clin Immunol; 2017 May; 13(5):469-482. PubMed ID: 27899043 [TBL] [Abstract][Full Text] [Related]
22. Systemic sclerosis-associated interstitial lung disease treated with tocilizumab. Dauny V; Borie R; Forien M; Ghanem M; Palazzo E; Jelin G; Dieudé P; Ottaviani S Intern Med J; 2021 Jun; 51(6):999-1000. PubMed ID: 34155759 [No Abstract] [Full Text] [Related]
23. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Jordan S; Distler JH; Maurer B; Huscher D; van Laar JM; Allanore Y; Distler O; Ann Rheum Dis; 2015 Jun; 74(6):1188-94. PubMed ID: 24442885 [TBL] [Abstract][Full Text] [Related]
24. Rituximab in the treatment of systemic sclerosis-associated interstitial lung disease: comment on the article by Yoo. Daoussis D; Andonopoulos AP Rheumatol Int; 2011 Jun; 31(6):841-2. PubMed ID: 20376665 [TBL] [Abstract][Full Text] [Related]
25. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Khanna D; Lin CJF; Furst DE; Goldin J; Kim G; Kuwana M; Allanore Y; Matucci-Cerinic M; Distler O; Shima Y; van Laar JM; Spotswood H; Wagner B; Siegel J; Jahreis A; Denton CP; Lancet Respir Med; 2020 Oct; 8(10):963-974. PubMed ID: 32866440 [TBL] [Abstract][Full Text] [Related]
26. Percentage of residual B cells after 2 weeks of rituximab treatment predicts the improvement of systemic sclerosis-associated interstitial lung disease. Ebata S; Yoshizaki A; Fukasawa T; Yoshizaki-Ogawa A; Asano Y; Kashiwabara K; Oba K; Sato S J Dermatol; 2022 Jan; 49(1):179-183. PubMed ID: 34661314 [TBL] [Abstract][Full Text] [Related]
27. [B cell abnormalities and therapeutic strategies in systemic sclerosis]. Yoshizaki A Nihon Rinsho Meneki Gakkai Kaishi; 2016; 39(3):197-206. PubMed ID: 27320935 [TBL] [Abstract][Full Text] [Related]
28. Reduced type I collagen gene expression by skin fibroblasts of patients with systemic sclerosis after one treatment course with rituximab. Fraticelli P; De Vita S; Franzolini N; Svegliati S; Scott CA; Tonnini C; Spadoni T; Gabrielli B; Pomponio G; Moroncini G; Gabrielli A Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S160-7. PubMed ID: 26339895 [TBL] [Abstract][Full Text] [Related]
29. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden. Wadström H; Frisell T; Askling J; JAMA Intern Med; 2017 Nov; 177(11):1605-1612. PubMed ID: 28975211 [TBL] [Abstract][Full Text] [Related]
30. Treatment of Systemic Sclerosis-related Interstitial Lung Disease: A Review of Existing and Emerging Therapies. Volkmann ER; Tashkin DP Ann Am Thorac Soc; 2016 Nov; 13(11):2045-2056. PubMed ID: 27560196 [TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of abatacept, tocilizumab and TNF-inhibitors compared with rituximab as second-line biologic drug in rheumatoid arthritis. Huoponen S; Aaltonen KJ; Viikinkoski J; Rutanen J; Relas H; Taimen K; Puolakka K; Nordström D; Blom M PLoS One; 2019; 14(7):e0220142. PubMed ID: 31339961 [TBL] [Abstract][Full Text] [Related]
32. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. Distler O; Highland KB; Gahlemann M; Azuma A; Fischer A; Mayes MD; Raghu G; Sauter W; Girard M; Alves M; Clerisme-Beaty E; Stowasser S; Tetzlaff K; Kuwana M; Maher TM; N Engl J Med; 2019 Jun; 380(26):2518-2528. PubMed ID: 31112379 [TBL] [Abstract][Full Text] [Related]
33. Interstitial lung disease in systemic sclerosis: pathophysiology, current and new advances in therapy. Jain S; Shahane A; Derk CT Inflamm Allergy Drug Targets; 2012 Aug; 11(4):266-77. PubMed ID: 22506881 [TBL] [Abstract][Full Text] [Related]
34. Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study. Elhai M; Meunier M; Matucci-Cerinic M; Maurer B; Riemekasten G; Leturcq T; Pellerito R; Von Mühlen CA; Vacca A; Airo P; Bartoli F; Fiori G; Bokarewa M; Riccieri V; Becker M; Avouac J; Müller-Ladner U; Distler O; Allanore Y; Ann Rheum Dis; 2013 Jul; 72(7):1217-20. PubMed ID: 23253926 [TBL] [Abstract][Full Text] [Related]
35. Management of interstitial lung disease in systemic sclerosis: lessons from SLS and FAST. Fathi N; Furst DE; Clements PJ Curr Rheumatol Rep; 2007 May; 9(2):144-50. PubMed ID: 17502045 [TBL] [Abstract][Full Text] [Related]
36. Unprecedented success of rituximab therapy for prednisolone- and immunosuppressant-resistant systemic sclerosis-associated interstitial lung disease. Ebata S; Yoshizaki A; Fukasawa T; Nakamura K; Yamashita T; Miura S; Saigusa R; Ichimura Y; Takahashi T; Hirabayashi M; Taniguchi T; Akamata K; Asano Y; Sato S Scand J Rheumatol; 2017 May; 46(3):247-252. PubMed ID: 27900875 [No Abstract] [Full Text] [Related]
37. The efficacy of treatment for systemic sclerosis interstitial lung disease: results from a meta-analysis. Broad K; Pope JE Med Sci Monit; 2010 Sep; 16(9):RA187-90. PubMed ID: 20802426 [TBL] [Abstract][Full Text] [Related]
38. Emerging drugs and therapeutics for systemic sclerosis. Lee JJ; Pope JE Expert Opin Emerg Drugs; 2016 Dec; 21(4):421-430. PubMed ID: 27813423 [TBL] [Abstract][Full Text] [Related]